GLPG0634 Shows Selective Inhibition of JAK1 and Maintained JAK-STAT Suppression in Healthy Volunteers

被引：0
|
作者：
Vanhoutte, Frederic [1 ]
Galien, Rene [2 ]
Vets, Eva [3 ]
Namour, Florence [2 ]
Vayssierre, Beatrice [2 ]
Van Rompaey, Luc [1 ]
Smets, Bart [1 ]
Brys, Reginald [1 ]
Wigerinck, Piet [1 ]
van 't Klooster, Gerben [1 ]
机构：
[1] Galapagos NV, Mechelen, Belgium
[2] Galapagos SASU, Romainville, France
[3] SGS, Antwerp, Belgium
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2210
引用
收藏
页码：S862 / S863
页数：2
相关论文
共 50 条
  • [31] SAFETY AND EFFICACY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A 4-WEEK PHASE II A DOSE RANGING, MULTI-CENTER TRIAL
    Vanhoutte, F. P.
    Van der Aa, A.
    Meuleners, L.
    van 't Klooster, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 242 - 242
  • [32] DOSE SELECTION OF GLPG0634, A SELECTIVE JAK1 INHIBITOR, FOR RHEUMATOID ARTHRITIS PHASE 2B STUDIES: PK/PD AND EXPOSURE-DAS28 MODELING APPROACH
    Namour, F.
    Tasset, C.
    van't Klooster, G.
    Diderichsen, P. M.
    Cox, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 220 - 221
  • [33] IDENTIFICATION OF A GENE SIGNATURE AND RESPONSE BIOMARKERS IN CIRCULATING LEUKOCYTES OF RA PATIENTS AFTER TREATMENT WITH THE JAK1-SELECTIVE INHIBITOR FILGOTINIB (GLPG0634)
    Ongenaert, M.
    Dupont, S.
    Vayssiere, B.
    Meuleners, L.
    Brys, R.
    Galien, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1068 - 1068
  • [34] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Westhovens, R.
    Alten, Rieke
    Pavlova, Dace
    Enriquez-Sosa, Favio
    Mazur, Minodora
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [35] Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach.
    Namour, Florence
    Tasset, Chantal
    Vayssierre, Beatrice
    van 't Klooster, Gerben
    Diderichsen, Paul
    Cox, Eugene
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S650 - S651
  • [36] HPP1 tumor suppression and JAK-STAT signaling
    Elahi, Abul
    Hernandez, Jonathan M.
    Shibata, David
    CANCER RESEARCH, 2010, 70
  • [37] The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies
    Genovese, Mark C.
    Westhovens, R.
    Kavanaugh, Arthur
    Meuleners, Luc
    Van der Aa, Annegret
    Harrison, Pille
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [38] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis
    Vermeire, Severine
    Schreiber, Stefan
    Petryka, Robert
    Kuehbacher, Tanja
    Hebuterne, Xavier
    Roblin, Xavier
    Klopocka, Maria
    Goldis, Adrian
    Wisniewska-Jarosinska, Maria A.
    Baranovsky, Andrei
    Sike, Robert
    Tasset, Chantal T.
    Van der Aa, Annegret
    Harrison, Pille
    GASTROENTEROLOGY, 2016, 150 (04) : S1267 - S1267
  • [39] 4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL
    Galien, Rene
    Harrison, Pille
    Brys, Reginald
    Van der Aa, Annegret
    van't Klooster, Gerben
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [40] Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
    Kavanaugh, A.
    Kremer, J.
    Ponce, L.
    Cseuz, R.
    Reshetko, O. V.
    Stanislavchuk, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 1009 - 1019
12345